Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30

Benzinga · 4d ago
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.